home / stock / fnch / fnch news

FNCH News and Press, Finch Therapeutics Group Inc. From 01/24/23

Stock Information
Company Name: Finch Therapeutics Group Inc.
Stock Symbol: FNCH
Market: NASDAQ
Website: finchtherapeutics.com
Menu
FNCH FNCH Quote FNCH Short FNCH News FNCH Articles FNCH Message Board
Get FNCH Alerts

News, Short Squeeze, Breakout and More Instantly...
FNCH - Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile ...
FNCH - Seres Gets Closer To Good Times

Summary After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. The FDA provides a firm date (April 26, 2023) for its decision concerning approval of SER-109. Big focus on SER-155 and other bacterial infections to follow SER-10...

FNCH - Finch Therapeutics GAAP EPS of -$0.85 misses by $0.45

Finch Therapeutics press release ( NASDAQ: FNCH ): Q3 GAAP EPS of -$0.85 misses by $0.45 . Finch’s cash and cash equivalents as of September 30, 2022 were $85.3 million, compared to $133.5 million as of December 31, 2021. Finch believes its cash and cash equival...

FNCH - Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDI Topline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” ...
FNCH - Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel ...

FNCH - Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel clas...

FNCH - Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch Therapeutics ( NASDAQ: FNCH ) on Thursday said it planned to cut its workforce by about 37% as part of a strategic review initiated due to Japanese pharmaceutical major Takeda's ( NYSE: TAK ) decision to discontinue its inflammatory bowel disease (IBD) collaborat...
FNCH - Finch Therapeutics Provides Business Update

SOMERVILLE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel cla...

FNCH - Finch to get back rights to IBD product candidates after Takeda ends collaboration

Finch Therapeutics Group ( NASDAQ: FNCH ) on Thursday said Japanese pharmaceutical major Takeda ( NYSE: TAK ) had ended their collaboration and that it would regain rights to investigational microbiome products FIN-524 and FIN-525. FNCH had signed a development and...

FNCH - Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD

SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel clas...
Previous 10 Next 10